Instil Bio, Inc. Increase Decrease In Operating Lease Liability
Instil Bio, Inc. (TIL) reported Increase Decrease In Operating Lease Liability of -$151.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Instil Bio, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$75.00K.
- Instil Bio, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$76.00K.
- Instil Bio, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $168.00K.
- Instil Bio, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$51.00K.
- Instil Bio, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.39M.
- Instil Bio, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.38M.
- Instil Bio, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.40M.
- Instil Bio, Inc. increase decrease in operating lease liability for fiscal 2022 was -$335.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$151.00K 10-Q · filed 2026-08-13 | $17.00K derived: sum of 3 quarters · filed 2026-08-13 | -$34.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$76.00K 10-Q · filed 2026-05-15 | $92.00K derived: sum of 2 quarters · filed 2026-05-15 | $41.00K derived: sum of 3 quarters · filed 2026-05-15 | -$1.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $117.00K derived: sum of 2 quarters · filed 2026-03-27 | -$1.23M derived: sum of 3 quarters · filed 2026-08-13 | -$1.39M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.40M derived: sum of 2 quarters · filed 2026-08-13 | -$1.56M 10-Q · filed 2025-11-13 | -$1.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.51M 10-Q · filed 2026-08-13 | -$1.89M derived: sum of 3 quarters · filed 2026-08-13 | -$2.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$163.00K 10-Q · filed 2026-05-15 | -$545.00K derived: sum of 2 quarters · filed 2026-05-15 | -$906.00K derived: sum of 3 quarters · filed 2026-05-15 | -$1.34M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$743.00K derived: sum of 2 quarters · filed 2026-03-27 | -$1.18M derived: sum of 3 quarters · filed 2026-03-27 | -$1.38M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$795.00K derived: sum of 2 quarters · filed 2025-11-13 | -$995.00K 10-Q · filed 2025-11-13 | -$1.20M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$434.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$634.00K 10-Q · filed 2025-08-13 | -$840.00K derived: sum of 3 quarters · filed 2025-08-13 | -$1.50M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$200.00K 10-Q · filed 2025-05-13 | -$406.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.06M derived: sum of 3 quarters · filed 2025-05-13 | -$1.16M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$865.00K derived: sum of 2 quarters · filed 2025-03-04 | -$958.00K derived: sum of 3 quarters · filed 2025-03-04 | -$1.40M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$752.00K derived: sum of 2 quarters · filed 2024-11-13 | -$1.20M 10-Q · filed 2024-11-13 | -$1.31M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$539.00K 10-Q · filed 2024-08-13 | -$649.00K derived: sum of 3 quarters · filed 2024-08-13 | -$778.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$446.00K 10-Q · filed 2024-05-10 | -$556.00K derived: sum of 2 quarters · filed 2024-05-10 | -$685.00K derived: sum of 3 quarters · filed 2024-05-10 | -$325.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$239.00K derived: sum of 2 quarters · filed 2024-03-21 | $121.00K derived: sum of 3 quarters · filed 2024-03-21 | -$335.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | -$129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $231.00K derived: sum of 2 quarters · filed 2023-11-13 | -$225.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$96.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$456.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |